Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.07.015 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Tuğba Akın Telli und 35 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Demiroğlu Bilim University Faculty of Medicine, Florence Nightingale Hospital, Istanbul, Turkey. Electronic address: tu…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins B-raf, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Real-world data on BRAF-mutant non-small cell lung cancer (NSCLC) remain limited, particularly regarding outcomes with dabrafenib plus trametinib (D + T). METHODS: This multicenter retrospective study included 88 patients with advanced BRAF-mutant NSCLC treated across 30 centers. Clinicopathologic characteristics, treatment outcomes, and safety data were collected and analyzed. Patients received either chemotherapy or dabrafenib plus trametinib in the first-line or subsequent settings. Progression-free survival (PFS), overall survival (OS), and objective response rates (ORR) were compared across treatment groups. RESULTS: Among 88 patients (78 V600E, 10 non-V600E), median age was 64 years. Co-mutations were more frequent in non-V600E cases (40% vs. 10%). Brain metastases were more frequent in non-V600E cases (60% vs. 15%, p = .001). First-line D + T was associated with superior ORR (67% vs. 39%, p = .02), DCR (81% vs. 51%, p = .009), and PFS (median 13.1 vs. 6.1 months, p = .007) compared to chemotherapy, while OS was similar between groups. Among chemotherapy regimens, platinum-pemetrexed outperformed platinum-taxane in terms of ORR (77% vs. 33%, p = .006) and PFS (median 14.7 vs. 3.2 months, p = .002). No significant differences in efficacy were observed between first-line and later-line use of D + T. Co-mutations were associated with shorter OS (median 8.7 vs. 20.2 months, p = .009). PD-L1 status and BRAF subtype did not impact OS. Median treatment duration with D + T was 10.6 months, with treatment-related adverse events occurring in 61% of patients, most commonly fatigue and pyrexia. CONCLUSIONS: In this real-world cohort, dabrafenib plus trametinib was associated with superior response rates and PFS compared to chemotherapy in the first-line setting. Presence of co-mutations was associated with poorer outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Demiroğlu Bilim University Faculty of Medicine, Florence Nightingale Hospital, Istanbul, Turkey. Electronic address: tugbaakintelli@gmail.com.
- Division of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
- Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, Turkey.
- Division of Medical Oncology, Gulhane Training and Research Hospital, Ankara, Turkey.
- Division of Medical Oncology, Ankara Ataturk Senatorium Training and Research Hospital, Ankara, Turkey.
- Division of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey.
Zitieren
APA
Telli, T. A., Tatlı, A. M., Alan, Ö., Keskin, G. Y., Karadurmuş, N., Karakaya, S., Kaplan, M. A., Açıkgöz, Ö., Bilici, A., Mocan, E. E., Demirkazık, A., Kahraman, S., Şendur, M. A., Doğan, M., Selam, M. T., Er, Ö., Ünsal, O., Yazıcı, O., Özcan, E., …, & Yumuk, P. F. (2025). Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.015
Vancouver
Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, et al. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.015
BibTeX
@article{Telli2025,
author = {Telli, Tuğba Akın and Tatlı, Ali Murat and Alan, Özkan and Keskin, Gülsema Yıldıran and Karadurmuş, Nuri and Karakaya, Serdar and Kaplan, Muhammet Ali and Açıkgöz, Özgür and Bilici, Ahmet and Mocan, Eda Eylemer and Demirkazık, Ahmet and Kahraman, Seda and Şendur, Mehmet An and Doğan, Mutlu and Selam, Meltem Topalgökçeli and Er, Özlem and Ünsal, Oktay and Yazıcı, Ozan and Özcan, Erkan and Kargı, Ayşegül and Gürbüz, Mustafa and Selçukbiricik, Fatih and Şakalar, Teoman and Gürsoy, Pınar and Bilgin, Burak and Selvi, Oğuzhan and Karadağ, İbrahim and Eren, Orhan Önder and Bayram, Ertuğrul and Sümbül, Ahmet Taner and Keskin, Serkan and Öztürk, Akın and Topçu, Sevgi and Özen, Miraç and Kılıçkap, Saadettin and Yumuk, Perran Fulden},
title = {Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.07.015}
}
EUVIMED